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Available online 14 October 2016Neuroﬁbromatosis type 1 (NF1) is a commonly occurring genetic disorder in children. Mutation in the NF1 gene
has its implication in poor osteoblastic capabilities. We hypothesised that pamidronate will enhance the osteo-
blastic potential of themesenchymal stemcells (MSCs) derived from lipoﬁbromatosis tissue of childrenwith con-
genital pseudarthrosis tibia (CPT) associated with NF1. In this study, bone marrow MSCs (BM MSCs) and CPT
MSCs were obtained from three patients undergoing salvage surgeries/bone grafting (healthy controls) and
those undergoing excision of the hamartoma and corrective surgeries respectively. The effects of pamidronate
(0, 10 nM, 100 nM and 1 μM) on cell proliferation, toxicity and differentiation potential were assessed and the
outcome was measured by staining and gene expression. Our outcome showed that CPT MSCs had more prolif-
eration rate as compared to BMMSCs. All 3 doses of pamidronate did not cause any toxicity to the cells in both the
groups. The CPTMSCs showed less differentiation with pamidronate compared to the healthy control MSCs. This
was quantitated by staining and gene expression analysis. Therefore, supplementation with pamidronate alone
will not aid in bone formation in patients diagnosed with CPT. An additional stimulus is required to enhance
bone formation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pamidronate1. Introduction
Congenital pseudarthrosis of the tibia (CPT) is associated with neu-
roﬁbromatosis type 1 (NF1). NF1 is caused by a mutation in NF1 gene
resulting in production of non-functional neuroﬁbromin protein (Shen
et al., 1996). This results in dysregulation of the Ras-Mitogen activated
protein kinases (MAPK) pathway which in turn affects the osteoblastic
differentiation adversely (Cho et al., 2008). It is well known that there
is generalized osteoporosis in NF1 affected individuals (Stevenson et
al., 2007). One of the major phenotypic manifestations of NF1 which
concerns orthopaedic surgeons is CPT (Schindeler and Little, 2008).
These individuals present with fractures of the lower tibia and ﬁbula
at birth or early childhood (Fig. 1a, b). The fractured or bowed abnormal
sclerotic and dysplastic bone is surrounded by a lipo-ﬁbromatous
hamartoma (Fig. 1c). This hamartoma is considered as the key patholo-
gy (Ippolito et al., 2000) and its complete removal is an essential part oft, Christian Medical College, Ida
. Madhuri),
ail.com (K. Rajagopal),
re.ac.in (B. Antonisamy).
. This is an open access article undertreatment of CPT (Birke et al., 2010). The fundamental issue which has
been the subject of investigations at the cellular level is the characteris-
tics of the stem cells isolated from this hamartoma (Lee et al., 2011).
Previous researchers have shown that these mesenchymal stem cells
(MSCs) have poor capacity for osteoblastic differentiation and a high
tendency for osteoclastogenesis (Cho et al., 2008). When fracture
union is achieved with surgical means there is a tendency for bowing
and re-fractures in the following years presumably due to the low
level of osteogenesis in the affected bone (Shah et al., 2012), unless sup-
ported by internal and external splinting.
There is a growing consensus in favour of using bisphosphonates to
prevent fractures and re-fractures in congenital pseudarthrosis (Birke et
al., 2010). The role of these nitrogen based compounds in preventing os-
teoclastic resorption is well known. Bisphosphonates cause apoptosis of
osteoclasts and negatively affect the oncogenes (Ras, Rab and Rho) re-
sponsible for membrane trafﬁcking and thus decrease osteoclast
proliferation.
Preliminary animal and clinical studies show that co-treatmentwith
systemic zoledronic acid, another bisphosphonate that improves net
bone production, also promotes healing in cases of CPT by inhibiting
the osteoclastic bone loss (Birke et al., 2010; Riebeling et al., 2002).
While the effect of pamidronate on the osteoclasts is well understood,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a) b) c)
Fig. 1. a: Lateral radiograph of a patientwith congenital pseudarthrosis of tibia showing atrophic, bowed and narrow tibial bone and a false joint at themid and distal third of the shaft. The
ﬁbula is also affected. b: T1 weighted MR image showing hypointense pseudarthrosis with surrounding hypointense ﬁbromatous tissue (red arrow). c Excised specimen from the
pseudarthrosis site including the bone ends and the surrounding ﬁbrous hamartoma.
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commonly used bisphosphonate has been shown to decrease viability
and proliferation in human alveolar osteoblasts by researchers (Marolt
et al., 2012). However, literature lacks studies on the effect of
pamidronate on the osteoblastic potential of MSCs derived from ﬁbrous
hamartoma in CPT associated with NF1 as compared it those from bone
marrow MSCs (BM MSCs).
This study aims to characterize the in vitro osteoblastic and
adipogenic potentials of MSCs derived from lipo-ﬁbromatous tissue iso-
lated from CPT with clinical manifestations of neuroﬁbromatosis using
BM MSCs as control (from healthy patients), and also study the effect
of pamidronate on cell viability, proliferation and differentiation
potential.2. Materials and methods
This study was approved by the Institutional Review Board. CPT and
BMMSCs used in this experiment were isolated from the discarded tis-
sue from children after informed consent from the parents.2.1. Isolation of MSCs from ﬁbrous hamartoma tissue
The discarded ﬁbrous hamartoma tissue was harvested from three
patients (2 females, one male with a mean age 5.3 years) with CPT un-
dergoing excision of the hamartoma and corrective surgery. All of these
patients were associated with café au lait spots of more than ﬁve in
numbers and a histological ﬁbrous hamartoma consistentwith CPT. Tis-
sue was collected in a 50 ml centrifuge tube containing DMEM/F12
(Sigma Aldrich, St Louis, USA). The time taken to transport the sample
to the lab was 1 h. The tissue was washed twice with phosphate buff-
ered saline and minced which were then kept for overnight digestion
(in CO2 incubator) using 1mg/ml collagenase type II (Worthington Bio-
chemicals, New Jersy, U.S.A.) in DMEM/F12. Following incubation, the
cell suspension was ﬁltered through 100 μm cell strainer (BD Falcon,
Bedford, USA) andwas centrifuged at 2000 rpm for 10min at room tem-
perature. Thus the MSCs from CPT was cultured in DMEM/F12 supple-
mented with 10% FBS.2.2. Isolation of bone marrow MSCs (BM MSCs) from trabecular bone
The trabecular bonewas harvested from three patients (3males and
mean age 5.6 years) undergoing deformity correction or bone grafting
(healthy control). Discarded tissue was collected in a 50 ml centrifuge
tube containing α-MEM media and transported to the lab for process-
ing. BMMSCs (healthy control MSCs) from trabecular bonewere isolat-
ed according to a previously published protocol (Sakaguchi et al., 2004).
The cells were cultured inα-MEMwith 10% FBS, 1% glutamine. The cells
from both CPT and healthy control MSCs at passage 3 were used for the
study.
2.3. MSC characterization
MSCs were characterized using cluster of differentiation (CD)
markers by ﬂow cytometry. MSCs speciﬁc markers such as CD73, and
CD105 and negative markers CD14, CD34 and CD45 were used.
2.4. Cell proliferation assay
Pamidronate concentrations used in this study were selected based
on the pharmacokinetics data provided in the drug data sheet. After in-
fusion of clinical dose, maximum pamidronate concentration of 10 nM/
ml of plasma will be achieved. Therefore we added 10 nM to 1 μM of
pamidronate to the culture medium to assess cytotoxicity and effect
on cell proliferation.
Cells were seeded at density of approximately 1500 cells/cm2. After
48 h of incubation the cells were treated with increasing concentration
of pamidronate (no pamidronate, 10 nM, 100 nM and 1 μM) to check
the effect of pamidronate on the cell proliferation. Assessment was
done at three different time points namely 24, 48 and 72 h after incuba-
tion in triplicates. Cells were counted using Trypan Blue dye exclusion
method.
2.5. Cytotoxicity test
The cytotoxic effect of pamidronate (0nM, 10nM, 100 nMand1 μM)
on cells (CPT and healthy control MSCs) was evaluated by MTT assay.
294 V. Madhuri et al. / Bone Reports 5 (2016) 292–298Cells were cultured in 96well plates (seeding density 25,000 cells/cm2)
with complete media (DMEM/F12 with 10% FBS) and maintained in a
CO2 Incubator. After 48 h of incubation, culture media was replaced
with that containing pamidronate in 0 nM, 10 nM, 100 nM and 1 μM
concentration. MTT assay was performed after further incubation of
24, 48 and 72 h in triplicates. MTT reagent (5 mg/ml) was added to
the culture and incubated in dark condition for 5 h. The absorbance
wasmeasured at 550 nmwith a reference ﬁlter at 620 nm usingMicro-
plate reader (Thermo Scientiﬁc).
2.6. Cell differentiation
MSCswere cultured in 24well plates at a seeding density of approx-
imately 4000 cells/cm2 and the cells were differentiated into osteoblast
and adipocyte with and without pamidronate (1 μM). The osteogenic
differentiation medium used was DMEM/F12 containing 10% FBS,
10 nM Dexamethasone, 10 mM beta glycerophosphate, and 50 μg/ml
Ascorbic acid, while the adipogenic differentiation medium was
DMEM/F12 containing 10% FBS, 10 μm 3- Isobutyl-1- methyl xanthine,
10 μg/ml Insulin, 100 μm Indomethacin and 1 μm dexamethasone. Dif-
ferentiation was carried out for 28 days and was qualitatively assessed
by Alizarin red (osteogenic) and Oil-O red (adipogenic) staining.
Image J software was used to compute the percentage of area stained
by a blinded observer. The analysis was repeated minimum three
times and expressed as percentage area stained ± SD.
2.7. Real time PCR
Total RNA was isolated using TRI Reagent (Sigma Aldrich, St Louis,
USA) as per themanufacturer's protocol. Isolated total RNAwas reverse
transcribed to cDNA using QuantiTect Reverse Transcription Kit
(Qiagen). Template DNA was used in gene-speciﬁc RT-PCR The relative
gene expression of osteogenic (RUNX2, ALPL, OSTEOCALCIN) and
adipogenic (PPARγ, FABP4 and LPL) markers were calculated by ΔΔCt
method and the results expressed in fold change. The sampleswere nor-
malized with GAPDH (housekeeping gene) as the reference gene to cal-
culate the ΔCt, which were further normalized with primary (day 0)
MSCs as a sample control to calculate the ΔΔCt. The target gene expres-
sion level was quantiﬁed by 2−ΔΔCt.
2.8. Statistics
Analysis of variance and Mann Whitney test were used to compute
the statistical signiﬁcance between the untreated and drug treatedFig. 2. Phase contrast images of mesenchymal stem cells (MSC) isolated from a) ﬁbrous hama
shaped morphology at 72 h after culture. Magniﬁcation ×10.groups. P b 0.05 was considered to be statistically signiﬁcant; graphs
are represented as mean (SD).
3. Results
3.1. MSC characterization
Phase contrast images of CPT MSC and healthy control MSC are
shown in Fig. 2. Flow cytometry in all three cases showed that the
cells isolated from CPT and healthy control hadMSC speciﬁc cell surface
markers. More than 95% of the cells were positive for CD73, CD105 and
about 1% stained positive for the negative markers (CD14, CD34 and
CD45) (Fig. S1).
3.2. Cell proliferation
Compared to the untreated group (0 nM pamidronate), all the three
doses (10 nM, 100 nM, 1 μM) of pamidronate used in this study did not
affect the proliferation in either the CPT or the healthy control MSCs
groups (Fig. S2, S3). Howeverwhen comparing CPTwith healthy control
MSCs, CPT MSCs have signiﬁcantly (P b 0.001) higher proliferation rate
than the healthy control MSCs at 72 h in all doses of pamidronate
(Fig.3).
3.3. MTT assay
Cytotoxicity as expressed by the formazan crystal colour changewas
not signiﬁcant in CPT and healthy control MSCs at different concentra-
tions of pamidronate (Fig.4).
3.4. Differentiation potential
Osteoblastic and adipogenic differentiation of CPT and healthy con-
trol MSCs at 28 days of culture with 1 μM pamidronate was assessed
both qualitatively by staining (Fig.5) and quantitatively by gene expres-
sion (Fig.6).
As shown in Fig. 5, CPTMSCswere stained 5%±1with Alizarin Red S
in the untreated (5a) and 2.33%± 0.68 in the pamidronate treated (5b)
groups; while Oil Red O stained 9.8% ± 1.9 and 6.46% ± 1.96 in the un-
treated (5c) and treated (5d) groups respectively. In the healthy control
MSCs, Alizarin Red S was stained 81% ± 7 and 81.5% ± 1.5 in the un-
treated (5e) and treated (5f) groups respectively. While Oil Red O was
quantiﬁed to be 12.4% ± 3.1 and 15.4% ± 5.6 in the untreated (5 g)
and treated (5 h) groups respectively.rtoma and b) bone marrow mesenchymal stem cells (healthy controls) showing spindle
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Fig. 3. Represents the cell count at 24, 48 and 72 h in congenital pseudarthrosis of tibia
(CPT) and BM MSCs (healthy controls). CPT MSCs were more proliferative than the
healthy control MSCs and the difference in cell number at 72 h was statistically
signiﬁcant (P b 0.001). Error bar represents standard deviation.
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Expression of osteoblast (Runx-2, alkaline phosphatase and
osteocalcin) and adipocyte (PPAR-γ, FABP4 and LPL) speciﬁc genes
were quantiﬁed by real time PCR (Fig. 6). Expression of Runx-2 and al-
kaline phosphatase with pamidronate was decreased by 2.2 fold and
1.7 fold respectively and the osteocalcin expression was decreased by
9.6 fold in CPT MSCs treated with pamidronate than the untreated
group. In contrast, healthy control MSCs treated with pamidronate
showed that the expression of Runx-2, alkaline phosphatase and
osteocalcin were up-regulated by 2.53, 7.7, and 6.5 folds respectively
than the untreated group. Expression of alkaline phosphatase by the
healthy control MSCs with pamidronate was signiﬁcantly higher
(P b 0.05) than the untreated MSCs.
Adipogenic differentiation of CPT cells were alsominimally inhibited
by pamidronate and the expression of PPAR-γ, FABP4 and LPL was re-
duced by 1.2, 2.02 and 1.7 folds respectively compared to the control
(no pamidronate) group. However in the healthy control MSCs, the ex-
pression of PPAR-γ (1.7 fold), FABP4 (1.2 fold) and LPL (1.43 fold) were
increased in the pamidronate group. Except for PPAR-γ, none of these
outcomes were statistically signiﬁcant (P N 0.05).
Qualitative and quantitative analysis showed that pamidronate en-
hanced the differentiation of healthy control MSCs into osteogenic and
adipogenic lineage marginally. However in CPT MSCs the presence of
pamidronate inhibited the differentiation into both lineages, more so
in osteoblastic lineage. Thus when comparing the results of CPT MSCs
with healthy control MSCs, the latter showed higher osteogenic and
adipogenic potential.Fig. 4. Cytotoxic effect of pamidronate (0, 10 nM, 100 nM, 1 μM) onmesenchymal stem cells (M
Error bar represents standard deviation.4. Discussion
The therapeutic effects of bisphosphonates in preventing osteoporo-
sis by inhibiting osteoclastic activity have been demonstrated experi-
mentally and clinically. Bisphosphonates also induce apoptosis of
osteoclasts by negatively regulating the Ras activity (Benford et al.,
2001). Due to their anti-catabolic properties they are being considered
formedical treatment of CPT (Birke et al., 2010). Clinically CPT is charac-
terized by decreased bone formation and remodelling at the affected
part of the tibia. In addition to this, there is resorption of bone in the af-
fected area and eventual pseudarthrosis. It has been shown that supple-
mentation with exogenous bone morphogenetic protein does not have
the desired effect in healing the pseudarthrosis (Lee et al., 2006).
The conventional surgical treatment for CPT includes stimulation of
bone formation by autologous bone grafting (Shah et al., 2012). In the
recent years, pamidronate and zoledronate are the drugs used to sup-
plement surgery. The therapeutic effect is mainly due to its anti-osteo-
clastic activity. There is no proof that bisphosphonates has an anabolic
effect on CPT similar to normal bone (Gou et al., 2014; Pan et al., 2004).
In this study, the cells were treated with increasing concentration of
pamidronate (0, 10 nM, 100 nM and 1 μM). None of these were toxic to
the cells in both healthy control and CPTMSCs as evidenced byMTT and
cell proliferation. Pamidronate at 1 μMwas used ﬁnally as it would en-
hance osteoblastic differentiation of CPTMSCs. This choicewas support-
ed by Marolt et al. (2012) where 1 μM of pamidronate showed
maximum alkaline phosphatase activity compared to 10 nM and
100 nM. This dosage was also selected based on literature and taking
into consideration reports of cell toxicity in concentrations above 3 μM
(Marolt et al., 2012). In the study byWassen et al. healthy bonemarrow
MSCswere used and he found that higher concentration of pamidronate
(10−5) decreased the osteoblastic differentiation while at lower con-
centration (10−9) increased osteogenic differentiation (Wassen et al.,
n.d.). In our study it was observed that the proliferation rate of CPT
MSCs was higher in all dosages of pamidronate but with a decreased
ability to differentiate to osteogenic and adipogenic lineages. This de-
crease in the differentiation was not signiﬁcant when compared to
healthy control MSCs. Pamidronate concentration at 1 μM increased
the osteogenic differentiation of healthy control bone marrow MSCs as
quantiﬁed by Alizarin Red S staining and gene expression.
In CPT the ﬁbrous hamartoma around the affected site has been con-
sidered as the key pathology. The progenitor cells derived from this
hamartoma have been shown to have cell surface markers similar to
MSCs. However, on differentiation they tend to have a lower osteoblas-
tic potential (Cho et al., 2008; Lee et al., 2011). The ﬁrst phase of our
study conﬁrmed that the progenitor cells isolated from the ﬁbrous
hamartoma had the characteristic cell surface markers CD 73, CD105SCs) isolated from a) congenital pseudarthrosis of tibia and b) healthy bonemarrowMSCs.
Fig. 5. Effect of pamidronate (1 μM) on osteogenic and adipogenic differentiation of mesenchymal stem cells (MSCs) isolated from a) congenital pseudarthrosis of tibia (CPT) (a–d) and
healthy bone marrow MSCs (e–h). CPT MSCs treated with pamidronate stained less with Alizarin Red S (b) and Oil O Red (d) than the untreated (a & c), whereas BM MSCs with
pamidronate stained more with Alizarin Red S (f) and Oil O Red (h) stain than the untreated group (e & g). Magniﬁcation ×20.
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those of healthy control MSCs derived from the trabecular bone. Other
authors have also isolated MSC like cells from ﬁbrous hamartoma
(Cho et al., 2008; Lee et al., 2011) but have not done a functional analysis
by looking for multi-lineage differentiation.
One of the deﬁning features ofMSCs is to differentiate into osteogen-
ic, adipogenic and chondrogenic lineages.We attempted to differentiate
the CPT hamartoma MSCs to osteogenic and adipogenic lineages and
compared the output with healthy control MSCs from trabecular bone.
Our study showed that CPT MSCs were capable of differentiating into
both adipogenic and osteogenic lineages. When compared to the
healthy control MSCs, the adipogenic and osteogenic differentiation
howeverwas lower in CPTMSCs. This establishes the poor ability to dif-
ferentiate into bone as a characteristic of the progenitor cells in
hamartoma (Andersen, 1973) and is probably a key factor in the devel-
opment of pseudarthrosis. This observation is similar to the work by
Granchi et al. who found poor osteogenic differentiation in the local
bone marrow at the affected site as compared to the iliac crest
(Granchi et al., 2012). However there are no studies that have differen-
tiated MSCs derived from the hamartoma and shown poor osteoblastic
differentiation with pamidronate.
Studies have shown that the osteogenic and adipogenic differentia-
tion of bone marrow is enhanced by bisphosphonates (Casado-Díaz et
al., 2013). Along with its osteoclastic activity, this is a major reason for
pamidronate having an anabolic effect on bone formation. If
pamidronate was to have a similar effect on the affected tibia in CPT,
then one could postulate that the therapeutic advantage of pamidronate
could be extended to an incipient fracture or an existing pseudarthrosis
rather than a purely supportive role following surgery.
In our study we found that pamidronate at a dose of 1 μM increased
the differentiation to both bone and adipose in healthy control MSCs,
thus demonstrating its anabolic effect. This response was not seen in
CPT MSCs which continued to have signiﬁcantly higher proliferation
rates occurring at the expense of lower differentiation to adipose and
bone when compared to the group without pamidronate and whenFig. 6. Effect of pamidronate (1 μM) on osteogenic and adipogenic differentiation of congenital
PCR. Bar diagram represents the relative fold change of RUNX2(a), ALPL (b) and osteocalcin (c),
with and without pamidronate (1 μM). Quantitative analysis was performed in triplicate and ge
and PPAR- γ in the healthy bonemarrowMSCswith pamidronatewas signiﬁcantly higher (P b 0
phosphatase, PPAR- γ - Peroxisome proliferator-activated receptor gamma, FABP4- fatty-acid-compared to healthy control MSCs. This was further evaluated by
performing gene expression studies which showed low expression of
alkaline phosphatase (osteogenicmarker) and PARR (adipogenic mark-
er). There are no previous studies on the hamartoma tissue highlighting
these ﬁndings.
We propose that the formation of periosteal hamartoma in congen-
ital pseudarthrosis is due to abnormally high proliferation associated
with poor differentiation capability of mesenchymal stem cells (El-
Hoss et al., 2012) residing in the local periosteum due to non-functional
negative regulation of Ras signalling pathway in neuroﬁbromatosis
(Abramowicz and Gos, 2013). Bisphosphonates should support the dif-
ferentiation by regulating the Ras protein in BMMSCs (von Knoch et al.,
2005). Our experiments show that this is not taking place in the MSCs
derived from periosteal hamartoma. From our study we conclude that
pamidronate has no role in increasing bone formation in the affected
area of CPT. However, based on the previous studies, it may have a
role in preventing resorption due to its osteoclastic activity. The clinical
implication of this ﬁnding is that pamidronate alone will not help in
healing of a fracture hamartoma or remodelling of a severely affected
bone. An additional stimulus such as an autologous bone graft which
provides BM MSCs to the affected site is mandatory to achieve good
union and remodelling.
There are few limitations in our study. We have characterized the
cells isolated from the ﬁbrous hamartoma by ﬂow cytometry. The cells
shared similar cell surface markers expressed in the bone marrow de-
rived MSCs. The cells were also able to differentiate in to osteo and
adipo lineages. This suggests that the isolated cells fromCPT are progen-
itor cells. However we have not looked at other parameters such as
maintenance of self-renewal and population doublings which distin-
guishes progenitor cells fromMSCs. Our experiments also had a limita-
tion in that they were performed in the absence of hydroxyapatite. In
vivo, the pamidronate binds to hydroxyapatite in the bone and thus
its effective concentration available to the periosteal MSCs may have
been much lower than the in vitro experiment. Further experiments
in the presence of calcium discs as carried out by Schindler et al. shouldpseudarthrosis of tibia (CPT) and healthy bone marrowMSCs were quantitated using RT-
PPAR-γ (d& e), FABP4 (f & g) and LPL (h& i) genes inCPT andhealthy controlMSCs treated
ne expression was normalized against the housekeeping gene GAPDH. Expression of ALPL
.05) than the untreated group. RUNX2 –Runt related transcription factor 2, ALPL – alkaline
binding proteins, LPL- Lipoprotein lipase.
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298 V. Madhuri et al. / Bone Reports 5 (2016) 292–298be performed (Schindeler and Little, 2005). However this does not alter
the conclusion that pamidronate doesn't provide an anabolic stimulus
to osteoblasts.
5. Conclusion
The CPT MSCs have a lower osteogenic potential than healthy con-
trolMSCs. Unlike healthy controlMSCs they do not show anosteoblastic
response to pamidronate in the dose of 1 μM. The fracture of CPT thus
requires an exogenous stimulus for osteogenesis.
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